AstraZeneca's Three-in-One COPD Inhaler Succeeds in Phase III Trial Post author:Sam Post published:January 25, 2018 Post category:BioPharma Astra has Glaxo and its COPD treatment Trelegy Ellipta squarely in its sights. Source: BioSpace You Might Also Like Asterias Biotherapeutics Extends The Expiration Date Of Certain Warrants And Provides Update On Cash Position February 2, 2017 Sanofi Genzyme Exec Exits to Become CMO of Flexion—Sanofi's Rumored Buyout Target April 6, 2017 Axovant CEO David Hung Abruptly Exits, COO and Several Directors Also Resign February 11, 2018
Asterias Biotherapeutics Extends The Expiration Date Of Certain Warrants And Provides Update On Cash Position February 2, 2017
Sanofi Genzyme Exec Exits to Become CMO of Flexion—Sanofi's Rumored Buyout Target April 6, 2017
